Petrichor Healthcare Capital Management
Overview
Petrichor Healthcare Capital Management partners with world-class healthcare managers and businesses to provide customized investment structures and support . The Petrichor team of investment professionals comes from highly-regarded financial institutions including OrbiMed Advisors and Fortress Investment Group . Collectively, the team has completed over 80 investments representing more than $5 billion in invested capital and has held over 30 board seats . Petrichor maintains a deep in-house understanding of healthcare products and services, including scientific, technical, and commercial expertise . This healthcare expertise, together with a breadth of experience investing across sectors, geographies, and capital structures, provides a unique combination to help build successful companies . Petrichor provides structured investments to support the development and commercial growth of innovative biopharmaceuticals, medical technologies, and services poised to transform the healthcare landscape .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Geneoscopy | Jan 2025 | Series C | Co-investor |
| Evergreen Theragnostics | Apr 2024 | Series C | Co-investor |
| Palvella Therapeutics | Jan 2023 | Series D | Lead |
| Aurion Biotech | Apr 2022 | Series C | Co-investor |
| Aurion Biotech | Oct 2019 | Series B | Co-investor |
Key People
Tadd Wessel
Founder, Managing Partner
Michael Beecham
Partner
Patrick Lally
Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.